2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-129694
    Lenoremycin
    		Inhibitor
    Lenoremycin (Ro 21-6150) is a microbial metabolite. Lenoremycin decreases β-catenin and cyclin D1 proteins levels. Lenoremycin decreases cancer stem cells (CSCs) populations via inducing reactive oxygen species production.
    Lenoremycin
  • HY-155153
    CDK9-IN-24
    		Inhibitor
    CDK9-IN-24 (compound 21a) is a highly selective CDK9 inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research.
    CDK9-IN-24
  • HY-151071
    TMX-3013
    		Inhibitor
    TMX-3013 is a CDKs inhibitor capable of inhibiting the activity of CDK1, CDK2, CDK4, CDK5, and CDK6, with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be utilized for synthesizing PROTACs that feature a polyethylene glycol (PEG) linker arm and Thalidomide (HY-14658) as the CRBN-recruiting arm.
    TMX-3013
  • HY-121081A
    BAY-1112054 hydrochloride
    		Inhibitor
    BAY-1112054 (BAY-958) (hydrochloride) is a potent PTEFb/CDK9 inhibitor with high selectivity demonstrated, particularly within the CDK family. BAY-1112054 (hydrochloride) shows strong antiproliferative activity against cancer cell lines such as HeLa and MOLM-13. BAY-1112054 (hydrochloride) exhibits good metabolic stability. BAY-1112054 (hydrochloride) effectively inhibits tumor growth in mouse xenograft models without significant toxicity.
    BAY-1112054 hydrochloride
  • HY-175187
    LO-3-63
    		Degrader
    LO-3-63, a Ribociclib (HY-15777) analog bearing a truncated fumaramide handle, is a PROTAC-like CDK4/6 degrader. LO-3-63 induces CUL4DCAF16-dependent degradation of CDK4/6 in cells.
    LO-3-63
  • HY-E70688
    CDK6/CycD3 Recombinant Human Active Protein Kinase
    CDK6 is a cell-cycle kinases that regulate exit from the G1 phase of the cell cycle. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. CDK6/CycD3 Recombinant Human Active Protein Kinase is an ortholog of CDK6.
    CDK6/CycD3 Recombinant Human Active Protein Kinase
  • HY-E70662
    CDK15/CycA2 Recombinant Human Active Protein Kinase
    CDK15 is a cell cycle-dependent kinase that is involved in tumor progression. CDK15/CycA2 Recombinant Human Active Protein Kinase is an ortholog of CDK15.
    CDK15/CycA2 Recombinant Human Active Protein Kinase
  • HY-151375
    CDK9/10/GSK3β-IN-1
    		Inhibitor
    CDK9/10/GSK3β-IN-1 (compound 13c) is a kinase inhibitor (Flavopiridol (HY-10005) analogue) that effectively inhibits HsGSK3β (IC50=59 nM), HsCDK9/CyclinT (IC50=64 nM), HsCDK5/p25 (IC50=1.093 μM) and HsCDK2/CyclinA (IC50=1.725 μM). CDK9/10/GSK3β-IN-1 has anti-cancer cellular activity comparable to or higher than that of Flavopiridol. CDK9/10/GSK3β-IN-1 shows high anti-proliferative activity in vitro against up to seven cancer cell lines.
    CDK9/10/GSK3β-IN-1
  • HY-15163A
    Zotiraciclib hydrochloride
    		Inhibitor
    Zotiraciclib hydrochloride is a novel small molecule multi-target enzyme inhibitor with activity in inhibiting tumor growth. Zotiraciclib hydrochloride exerts its anti-tumor effect by reducing the level of Myc through inhibiting cyclin-dependent kinase 9 (CDK9). Zotiraciclib hydrochloride may be useful for inhibiting cancers that cross the blood-brain barrier. The high protein level of MCL-1 of Zotiraciclib hydrochloride is associated with survival, suggesting that it may serve as a prognostic factor and inhibitory target in further studies.
    Zotiraciclib hydrochloride
  • HY-RS02349
    Cdk1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk1 Mouse Pre-designed siRNA Set A
  • HY-15260C
    XL413 hydrochloride
    		Inhibitor
    XL413 (BMS-863233) hydrochloride is an orally active and selective CDC7 inhibitor (IC50=3.4 nM). XL413 hydrochloride has favorable pharmacokinetic profiles and significantly inhibits tumor growth in rodent models. XL413 hydrochloride can be used in cancer research.
    XL413 hydrochloride
  • HY-E70660
    CDK13/CycK Recombinant Human Active Protein Kinase
    CDK13/CycK Recombinant Human Active Protein Kinase is a RNA polymerase II C-terminal domain kinases. CDK13 interacts with the splicing factor SRSF1 and to regulate alternative splicing of HIV.
    CDK13/CycK Recombinant Human Active Protein Kinase
  • HY-RS02363
    Cdk14 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk14 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk14 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk14 Mouse Pre-designed siRNA Set A
  • HY-136841
    SLM6
    		Inhibitor
    SLM6 is a sangivamycin-like molecule. SLM6 is a CDK9 inhibitor. SLM6 inhibits CDK9/cyclin K and CDK9/cyclin T1 kinase activity with IC50s of 280 nM and 133 nM, respectively. SLM6 also inhibits CDK1/cyclin B and CDK2/ cyclin A with IC50s of less than 300 nM. SLM6 induces apoptosis in multiple myeloma (MM) cells.
    SLM6
  • HY-118310
    Xylocydine
    		Inhibitor
    Xylocydine is an inhibitor of CDK1/2, inhibiting CDK function in various apoptotic processes. Xylocydine specifically blocks CDK1 and CDK2 activity with IC50 of 1.4 nM and 61 nM, respectively. In addition, Xylocydine downregulates phosphorylated nucleolin and retinoblastoma protein levels..
    Xylocydine
  • HY-147603
    CDK7-IN-18
    		Inhibitor
    CDK7-IN-18 is a potent inhibitor of CDK7. CDK7-IN-18 is a pyrimidinyl derivative compound. CDK7-IN-18 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 15).
    CDK7-IN-18
  • HY-144810
    CDK2-IN-8
    		Inhibitor
    CDK2-IN-8 is a potent CDK2 inhibitor with an IC50 of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma.
    CDK2-IN-8
  • HY-164619
    CDK9-IN-34
    		Inhibitor
    CDK9-IN-34 (Compound 1b) is an inhibitor for CDK9 with an IC50 of 0.25 μM. CDK9-IN-34 exhibits cytotoxicity to cancer cell HCT116, MCF7 and K652 with IC50s of 1.43, 3.01 and 50.27 μM, respectively. CDK9-IN-34 exhibits antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.
    CDK9-IN-34
  • HY-E70652
    CDK1/CycA2 Recombinant Human Active Protein Kinase
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK4/CycD2 Recombinant Human Active Protein Kinase is an ortholog of CDK1.
    CDK1/CycA2 Recombinant Human Active Protein Kinase
  • HY-162619
    CDK9-IN-33
    		Inhibitor
    CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity.
    CDK9-IN-33
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.